First-line mCapOX+Cetuximab vs. mFOLFOX6+Cetuximab for Metastatic Left-sided CRC With Wild-type RAS/BRAF Genes

Exclusion Criteria

• •Patients with mCRC who were initially resectable with R0 resection or radiofrequency or SBRT were excluded.
• •Patients diagnosed with MSI-H or dMMR by PCR or immunohistochemistry
• •Hypersensitivity to any therapeutic agent.
• •Patients who received adjuvant chemotherapy containing oxaliplatin and fluorouracil within 12 months before entering the study;
• •Patients who have failed one or more palliative chemotherapy regimens;
• •Patients with uncontrolled hepatitis B virus
• •Peripheral neuropathy ≥ CTC grade 2;
• •Neurological or psychiatric disorders affecting cognitive performance;
• •Patients with central nervous system metastasis could not be controlled with radiotherapy;
• •Previous enteritis, chronic diarrhea, or recurrent bowel obstruction; uncontrolled bleeding from internal medicine; bowel perforation
• •Uncontrolled concomitant diseases within 6 months before the study, including unstable angina, acute myocardial infarction, cerebrovascular accident, etc.;
• •Pregnant or lactating patients, or those of childbearing potential who do not take adequate contraceptive measures;
• •History of other malignancies, but no disease-free survival longer than 5 years;
• •Patients concurrently receiving other anti-tumor treatment or participating in other interventional clinical trials;
• •Patients who are unable to comply with this study for psychological, family or social reasons.
• •Patients with other serious diseases that the investigator considers not suitable.